IZOZF - Izotropic Unaware of Any Material Change
(TheNewswire)
October 26, 2020 - TheNewswire - At the request of IIROC, Izotropic Corporation("Izotropic Corporation" or the "Company") (CNSX:IZO.CN) (OTC:IZOZF) wishes to confirm that the Company's management is unaware ofany material change in the Company's operations that would account forthe recent increase in market activity.
"Izotropic Corporation" is engaged in thecommercialization of proprietary diagnostic products for breastcancer. Its business strategy is to complete the commercialdevelopment of 360 degree, true 3D breast imaging technology for earlydiagnosis of breast cancer. The Company holds a license under alicense agreement to make, have made, use, offer for sale, import, andsell products and services and to practice processes and methods inthe field of human diagnostics and therapeutics in the United Statesand any other countries where approvals are granted or where patentrights may exist in the future with respect to certain licensed patentrights.
This news release may contain assumptions, estimates,and other forward-looking statements regarding future events. Suchforward-looking statements involve inherent risks and uncertaintiesand are subject to factors, many of which are beyond the Company'scontrol that may cause actual results or performance to differmaterially from those currently anticipated in such statements.
FOR FURTHER INFORMATION PLEASECONTACT:
Robert Thast
Chief Executive Officer
Phone: 1-833-IZOCORP
Email: info@izocorp.com
Website: izocorp.com
About Izotropic Corp.
Izotropic Corporation and its wholly owned U.S.operating subsidiary, Izotropic Imaging Corp. have been established tocommercialize the next generation of breast imaging technology forearly diagnosis of breast cancer. The Izotropic Breast CT ImagingSystem produces high resolution breast images in 3D. A single 10second breast CT scan acquires approximately 500 images, withoutpainful breast compression, providing radiologists with fully 3Dviewing of the scanned breast. Mammography scanning requirescompression of the breast between 2 imaging plates, resulting in 2Dimages.
The Company has the exclusive worldwide license fromthe University of California, Davis to commercialize the technologydeveloped by principal founder and Company director Dr. John M. Booneand researchers at UC Davis. The license includes all intellectualproperty, trade secrets, patents and patent-pending applications thatare the foundation of the Company's breast CT imaging platform.
Approximately $20 million in research funding and over15 years of research and development have been invested in developingthis groundbreaking breast CT imaging technology. Research includes acurrent, ongoing $2.9M U.S. clinical trial at UC Davis Medical Center.
The Company founders believe that this technology willbe a disruptive entry to the market, overcoming many of the challengesfaced by existing breast imaging modalities.
Copyright (c) 2020 TheNewswire - All rights reserved.